|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In advanced CRCs, KRAS mutations occurred in 48% of cases (64% codons 12/13, 36% other codons) and BRAF mutations in 10% (66% V600E, 33% exon 11).
|
19474002 |
2009 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Mutation analysis of 66 arbitrary selected colorectal carcinomas revealed that CD274-positive tumors usually (88%) carried the BRAF V600E mutation.
|
27813511 |
2017 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Moreover, this method was proven to distinguish the BRAF V600E mutant from the wild type based on intrinsic differences by using a total of 312 CRC tissue samples paraffin-embedded, deparaffinized, and stained.
|
31208050 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E and SRC mutations are important molecular markers which can predict prognosis and conversion surgery in Stage IV CRC.
|
30792536 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E </span>mutation in colorectal cancer by immunohistochemistry is a viable alternative to molecular methods.
|
23650027 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Here, we measured the prevalence and epidemiologic correlates of the BRAF V600E somatic mutation in cases collected as a part of a population-based case-control study of CRC in northern Israel.
|
20200438 |
2010 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We conclude that a single endogenous BRAF(V600E) allele is sufficient to repress BIM and prevent death arising from growth factor withdrawal, and CRC cells with BRAF(V600E) mutations are addicted to the ERK1/2 pathway for repression of BIM and growth factor-independent survival.
|
18806830 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.
|
22210186 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
To summarize the usefulness of several recently discovered immunohistochemical markers in the study of gastrointestinal and liver tumors; to suggest the most current and effective immunohistochemical panels addressing common diagnostic challenges for these tumors; to share practical experience and useful tips for human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinoma and v-raf murine sarcoma viral oncogene homolog B V600E immunohistochemistry in colorectal carcinoma.
|
25549141 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
A correlation between MLH1 promoter methylation, specifically the 'C' region, and BRAF V600E status has been reported in CRC studies.
|
23880961 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
When subclassified by combined BRAF V600E mutation and MMR status, loss of ARID1A expression was found most commonly in CRCs with the BRAF V600E mutated, MMR- deficient phenotype (58 of 232 cases, 25%, P < .01).
|
24925223 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Activating V600E mutation in BRAF gene has been linked with widespread methylation of CpG islands in sporadic colorectal cancers.
|
21455633 |
2011 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients.
|
21681432 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The MSI-high status has also been described in sporadic colorectal cancer (CRC) associated with BRAF gene mutation (V600E); this mutation was not present in LS-associated cancers.
|
26096739 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib.
|
26810733 |
2016 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation is a poor prognostic factor in MSI-H metastatic CRC.
|
24585723 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients.
|
21587258 |
2011 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
V599E was observed in 12 of 19 (63%) polyps and 14 of 20 (70%) cancers (4 of 4 high MSI, 2 of 4 low MSI, and 8 of 12 stable MSI), a significant increase over HNPCC (0 of 15 or 0%), and unselected CRC (30 of 197 or 15.2%) ( P < .05).
|
15765445 |
2005 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The V600E mutation does not appear to be associated with microsatellite instability, unlike the case in colorectal cancer.
|
22246856 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
|
25613750 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Commonly observed alterations across sporadic CRCs have allowed classification into a (1) hypermutated group that includes defective DNA mismatch repair with microsatellite instability and POLE mutations in ∼15%, containing multiple frameshifted genes and BRAF(V600E); (2) nonhypermutated group with multiple somatic copy number alterations and aneuploidy in ∼85%, containing oncogenic activation of KRAS and PIK3CA and mutation and loss of heterozygosity of tumor suppressor genes, such as APC and TP53; (3) CpG island methylator phenotype CRCs in ∼20% that overlap greatly with microsatellite instability CRCs and some nonhypermutated CRCs; and (4) elevated microsatellite alterations at selected tetranucleotide repeats in ∼60% that associates with metastatic behavior in both hypermutated and nonhypermutated groups.
|
26216840 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Alterations in <i>MEK1/2</i> occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in <i>BRAF</i>-V600E-mutant melanoma and colorectal cancer.
|
28655712 |
2017 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer.
|
25176643 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after CRC diagnosis among subgroups of patients.
|
22899730 |
2012 |